Objective: Congestive heart failure with left ventricular (LV) diastolic dysfunction and preserved systolic function, i.e. diastolic heart failure (DHF), is often observed in hypertensive patients. Although angiotensin converting enzyme (ACE) inhibitors are widely used as antihypertensive therapy, there is a continued controversy about long-term effect of ACE inhibition on diastolic function. The current study was designed to elucidate a therapeutic effect of ACE inhibitor, temocapril, administration initiated after LV hypertrophy (LVH) and diastolic dysfunction are evident. Methods: Dahl salt sensitive rats fed on 8% NaCl diet from 7 weeks (hypertensive DHF model) were studied at 13 weeks (n56) or at 19 weeks following chronic administration of a subdepressor dose of temocapril (0.2 mg / kg / day, TEM(1), n56) or placebo (TEM(2), n57) from 13 weeks. Results: Compensatory LVH was associated with prolonged time constant of LV relaxation (Tau) at 13 weeks. In TEM(2), progression of LVH and fibrosis and elevation of LV end diastolic pressure were observed at 19 weeks. Administration of temocapril from 13 weeks prevented the further progression of LVH and fibrosis, attenuated increases in myocardial stiffness constant and Tau, and prevented the development of DHF. These effects were accompanied with the attenuation of decreases in sarcoplasmic reticulum calcium(21)-ATPase 2a and phosphorylated phospholamban and of hypertrophic signalings' upregulation. Conclusions: This study demonstrated that chronic administration of temocapril exerts a therapeutic effect on diastolic dysfunction and prevents the transition to DHF even if initiated after appearance of LVH and diastolic dysfunction.
T emocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction a a , a a
1 . Introduction strategy of DHF has not been established [1, 4] . Recently we have demonstrated that activation of renin angiotensin Congestive heart failure with left ventricular (LV) system is associated with the development of DHF in diastolic dysfunction and preserved systolic function, i.e.
hypertensive heart [5, 6] . Impairment of LV diastolic funcdiastolic heart failure (DHF), is often observed in hytion, and thus, development of DHF was prevented by pertensive patients, and consists of a high proportion of chronic angiotensin converting enzyme (ACE) inhibition patients with congestive heart failure [1,2]. The rate of or angiotensin II type 1 receptor blockade initiated at an hospitalization and the cost of health care associated with early stage when LV hypertrophy (LVH) and diastolic DHF rival those associated with systolic heart failure [3] . dysfunction were not evident [7] . However, there are very In general population, the mortality rate among patients little data pertaining to the effects of pharmacological with DHF is four times that among those without heart interventions initiated after LVH and diastolic dysfunction failure [3] . Nevertheless, pathophysiology or therapeutic are promoted. The current animal study was designed to elucidate a therapeutic effect of ACE inhibitor, temocapril, administra-tion in a subdepressor dose initiated after the appearance of 2 .1. Production of the model LVH and diastolic dysfunction in the DHF model. We previously demonstrated that hypertension gradually deLaboratory chow containing 0.3% NaCl was continuousvelops in Dahl-Iwai salt-sensitive rats fed on 8% NaCl ly fed to the male Dahl-Iwai salt-sensitive rats (DIS / Eis, from 7 weeks, followed by compensatory LVH and Eisai, Tokyo, Japan) and they were defined as control impaired relaxation at 13 weeks and in turn by the group (n56). Diet was switched to laboratory chow transition to DHF at about 20 weeks [5, 6] . Thus, the containing 8% NaCl at 7 weeks for the other male rats administration of temocapril was initiated from 13 weeks (n519). We randomly selected 6 out of 19 rats to study in this study. As an underlying cardiovascular disease in hemodynamic and pathological characteristics at 13 weeks this model is a hypertensive heart disease, antihypertensive (the 13wH group). Six out of the other 13 rats were therapy may well provide beneficial effects in this model. selected and given temocapril hydrochloride (0.2 mg / kg However, LV hypertrophy, one of the determinants of per day, courtesy of Sankyo: the TEM(1) group) by prognosis, frequently progresses in hypertensive patients gastric gavage from 13 weeks. The scheme of this study even under an antihypertensive therapy [8, 9] . This suggests protocol is shown in Fig. 1 . The dose of temocapril was that antihypertensive therapy is mandatory but not suffidetermined according to the data in a preliminary study cient, and pharmacological intervention is required to (unpublished data). The other 7 rats were given placebo provide beneficial effects on ventricular structure and (the TEM(2) group). The diet and tap water were given ad function independent of its hemodynamic effects. Thus, libitum throughout the experiment. Systolic blood pressure investigation of pharmacological effects of temocapril on was measured at 7, 13, 17 and 19 weeks using the tail cuff LV structure and diastolic function independent of its system [5] . depressor effect in DHF is likely to provide clinical implications, and a subdepressor dose was used in the 2 .2. Echo and hemodynamic studies current study.
Transthoracic echocardiographic studies were performed at 7, 13, 17 and 19 weeks to determine LV mass, mid-wall fractional shortening and relative wall thickness in a 2 . Methods fashion previously described [5, 10] . Specifically, rats were anesthetized with intraperitoneal administration of This study conforms with the guiding principles of ketamine HCl (50 mg / kg) and xylazine HCl (10 mg / kg), Osaka University Graduate School of Medicine with and were held in the half left-lateral position. Rats were regard to animal care, the American Heart Association on allowed to breathe spontaneously during the echo studies. research animal use, and the Guide for the Care and wall thickness at a paper speed of 100 mm / s. End muscle level in the slices stained with Azan Mallory stain at 3100 magnification was determined by previously systolic wall stress was calculated at 19 ATPase 2a (SERCA2a), phospholamban (PLN), and described [10, 13] .
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). Specifically, LV pressure tracing and M-mode echocarThese sequences of all oligo-nucleotides used as forward diogram were scanned into a computer system (Power primers, reverse primers and detection probes were shown Macintosh 7600 / 120, Apple Computer), and LV pressure, in Table 1 . To correct the efficiency of cDNA synthesis, internal diameter, and wall thickness were digitized over a the amounts of mRNAs were divided by the amounts of cardiac cycle. LV mean wall stress (s) was calculated using GAPDH mRNA and then, was normalized to a mean value the following equation:
of age-matched control group, respectively.
where P is LV pressure, D is LV short axis diameter and H 2 .7. Western blot analysis is wall thickness of the region of interest. Then, the diastolic s 2 ln(1 /H ) data points were fitted to a single Frozen LV tissues (|100 mg) were homogenized in 1.5 exponential curve with zero asymptote to calculate ml of ice-cold lysis buffer containing in mM Tris-HCl 50 myocardial stiffness constant:
(pH 7.4), sodium orthovanadate 0.1, sodium fluoride 50, sucrose 150, phenylmethylsulfonyl fluoride 1, benzamidine
1, EDTA 5, EGTA 2. Subsequently the samples were where K was determined as myocardial stiffness constant.
centrifuged at 10 0003g for 10 min. The pellet was The mean value of myocardial stiffness constant of the discarded and the protein content of the supernatant was septum and the posterior wall was used for statistical determined using the DC-protein assay (BioRad, Hercules, 16 analysis. CA, USA). For detection of SERCA2a, PLN and Serphosphorylated PLN, lysates were heated for 3 min at 2 .4. Tissue sampling 95 8C. Lysates containing equal amounts of protein (20 mg) were subjected to SDS-PAGE. Proteins were transEcho and hemodynamic studies were followed by ferred onto a nitrocellulose membrane according to the adequate anesthesia and the heart and the lung were manufacture's protocol. Membranes were blocked with 5% harvested to weigh the left ventricle and the lung in a nonfat dry milk 1 h and incubated with antibody to previously described fashion [5] . Samples of the left SERCA2a (Affinity Bioreagents, Golden, CO, USA), PLN 16 ventricle for the measurement of hydroxyproline content (generously gifted by Dr Jerrey Wang) and Ser -phosand the amounts of mRNAs and protein were immediately phorylatied PLN (Upstate Biotechnology, Charlottesville, placed in liquid nitrogen and stored at 280 8C [6].
VA, USA) overnight at 4 8C. Each membrane was also incubated with matched secondary antibody (horseradish 2 .5. Pathological studies peroxidase conjugated, KPL Laboratories). Protein bands were visualized using by enhanced chemiluminescence A part of the left ventricle was fixed with a phosphate-(Amersham Bioscience, Tokyo, Japan). The degree of buffered 10% formalin solution for a week. The specimens labeling was quantified by a computer program (NIH) and were embedded in paraffin, and 2-mm thick transverse expressed in relative units. sections of the organs were stained with hematoxylin and eosin for routine histological examination and with Azan 2 .8. Statistical analysis Mallory stain to evaluate the degree of fibrosis. The percent area of fibrosis in the left ventricle at the papillary Results are expressed as mean values6S.E.M. Parame- ters were compared with the use of a commercially increase thereafter in the TEM(1) group and LVMI was available statistical software (STATVIEW version 5.0, lower in the TEM(1) group than in the TEM(2) group at SAS Institute, Cary, NC, USA). Serial data were analyzed 19 weeks (Fig. 2) . The data of gravitational LV mass and using ANOVA for repeated measurements. Differences at LVMI at 19 weeks support the results obtained by echo specific stages among groups were assessed using one- (Table 3) . LV end-diastolic dimension at 19 weeks was not factor ANOVA and Bonferroni / Dunn's test. Differences different among the three groups (Table 2) . between the 13wH group and the TEM(1) group at 19 LV systolic function as assessed with midwall fractional weeks were assessed using unpaired t-test. A P value of shortening was not different among the control, TEM(2) less than 0.05 was considered statistically significant. and TEM(1) groups throughout the study period (Table   Table 2 Serial changes in the control group and the rats of group TEM(2) and 2). Tau was prolonged in both hypertensive groups at 19 3 .4. mRNA levels of hypertrophic and fibrotic weeks, but the prolongation was smaller in the TEM (1) stimulating signals group as compared with the TEM(2) group (Table 3) . End systolic wall stress was not different among the three
. Results
The mRNA levels of ANP and BNP were higher in the groups at 19 weeks (Table 3) . MSC was higher in both the TEM(2) group than in the control group. The administra-TEM(2) and TEM(1) groups than in the control group tion of temocapril significantly attenuated their gene but the increase was smaller in the TEM(1) group than in expression (Fig. 2) . The levels of prepro endothelin-1 and the TEM(2) group (Table 3) .
TGF-b mRNA were higher in the TEM(2) group than in 1 the control group. Treatment with temocapril reduced the increases (Fig. 3) . The expression of CT-1 mRNA was 3 .3. LV fibrosis lower in the TEM(2) group compared to the control group and its expression was upregulated by administration of Hydroxyproline content and percent area of fibrosis in temocapril (Fig. 3) . the left ventricle were significantly higher in the TEM(2) 21 group than in the control group (Table 3) , and histological 3 .5. mRNA and protein levels of Ca cycling proteins observation revealed perivascular and interstitial fibrosis particularly in the subendocardial portion in the TEM(2) Decreases in SERCA2a mRNA and protein levels were group. Reduction in hydroxyproline content and percent observed in the TEM(2) group but not in the TEM(1) area of fibrosis is noted in the TEM(1) group (Table 3) . group (Fig. 4 ). Neither mRNA nor protein level of PLN CT-15cardiotrophin-1.
was different among the three groups (Fig. 5) . However, the 13wH group (5165 vs. 4162%, P,0.05), indicating phosphorylation level of PLN decreased in the TEM (2) that chronic administration of temocapril attenuated concegroup compared to the control group and this decrease was ntric geometry without changes in LV mass or fibrosis. Tau prevented by temocapril (Fig. 5) .
was shortened by temocapril from 13 to 19 weeks (3161 vs. 2661 ms, P,0.05).
.6. Comparison of the data between before and after ACE inhibition
4 . Discussion In order to study therapeutic effects of temocapril, the data of the TEM(1) group at 19 weeks were compared Long-term administration of temocapril from the comwith those of the 13wH group. While gravitational LVMI pensatory hypertrophic stage prevented the decreases in (3.160.1 mg / g) and hydroxyproline content (3.060.2 SERCA2a and phosphorylated PLN and improved LV mmol / g) were not different between these groups, relative relaxation in hypertensive DHF model using Dahl saltwall thickness was smaller in the TEM(1) group than in sensitive rats. This treatment also prevented the further † progression of LVH and fibrosis, leading to attenuation of SERCA2a mRNA and protein expression [22] . Thus, the myocardial stiffening. Thus, long-term administration of improvement of LV relaxation by temocapril may be at temocapril, even if initiated after LVH and impaired LV least partly explained by its direct inhibition of SERCA2a relaxation are evident, exerts beneficial effects on LV downregulation through protein kinase C inhibition. Morediastolic function in hypertensive hearts. The benefit was over, long-term administration of temocapril attenuated the brought about independently of its antihypertensive effect decrease in phosphorylated PLN protein level without and was enough to prevent the transition to DHF. changing the mRNA or protein level of PLN. If important 21 roles of PLN in sarcoplasmic reticulum Ca transport 4 .1. Therapeutic effect of temocapril after compensatory system are considered [23] , functional alteration of PLN, hypertrophic stage on LV relaxation even without a change in protein level, may explain temocapril-induced improvement of LV relaxation. Effect of acute ACE inhibition on LV relaxation abnormality was reported in patients with severe LVH and 4 .2. Effect of temocapril after compensatory preserved systolic function [14] . However, effect of longhypertrophic stage on LV structure term ACE inhibition is still controversial in patients with LVH and abnormal relaxation [15, 16] . Although chronic Long-term administration of temocapril from the com-ACE inhibition prevented the deterioration of LV relaxapensatory hypertrophic stage restrained the further pro- 21 tion or of Ca uptake in previous in vivo studies gression of LVH (Fig. 2) and fibrosis (Table 3) . We [7, 17, 18] , the treatment in any of these studies was showed that progressive LVH after the compensatory initiated before the abnormalities were manifest. The hypertrophic stage in the DHF model is maladaptive and current study expanded the previous studies by demonexcessive and is likely induced with LV fibrosis by strating that long-term administration of temocapril atactivation of renin angiotensin system [7] . The excessive tenuated the advanced abnormality of LV relaxation. This LVH and LV fibrosis contribute to myocardial stiffening result is partly supported by the ex vivo study demonand are therapeutic targets for hypertensive DHF [10] . strating that the slowing of myocyte relaxation in hySome previous studies reported that ACE inhibition exerts pertrophied cardiac myocyte was reversed by ACE inhibibeneficial effects on LVH or fibrosis in animal models with tion [19] .
LV hypertrophy independently of its depressor effects LV relaxation is at least partly regulated by SERCA2a [24] [25] [26] [27] , however, other studies reported a lack of benefiactivity [20] . In this study, long-term administration of cial effects in subdepressor doses in pressure overload temocapril prevented the decrease in SERCA2a mRNA models [28] [29] [30] . In addition, the animal models used in the and protein levels, which is consistent with the previous previous studies develop systolic heart failure, not DHF. A studies of other ACE inhibitors [17, 21] . Angiotensin II recent trend is to consider that systolic heart failure and type 1 receptor-mediated signaling pathway activates DHF have different pathophysiology and that their theraprotein kinase C, and protein kinase C activation decreases peutic strategies should be different [31, 32] . Thus, the results of the previous studies cannot be easily extrapolated prevents the impairment of LV diastolic function if to DHF. The early initiation of ACE inhibitor or angioteninitiated before LVH or diastolic dysfunction is observed sin II type 1 receptor blocker before appearance of LVH or [7] . Taken together with the current results, ACE inhibition diastolic dysfunction prevented the excessive LVH, LV exerts therapeutic as well as preventive effects against the fibrosis and myocardial stiffening in the hypertensive DHF development of DHF in hypertensive hearts and may be a model independent of the depressor effects in other key therapeutic regimen for DHF as well as systolic heart previous study and ours [7, 33, 34] . The current study failure. expanded the previous studies by demonstrating that the similar benefits were obtained by the long-term ACE inhibition with temocapril in the hypertensive DHF model, A cknowledgements even if ACE inhibition was initiated after the appearance of LVH and LV relaxation abnormality.
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